drugset / Trial / NCT04576325

Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma

NCT04576325

Phase 1 Completed 17 enrolled TFF Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a Phase 1b, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetic profiles of voriconazole inhalation powder in adult subjects with well-controlled asthma. This study will involve 2 cohorts.

Timeline

Start
2020-11-15
Primary completion
2021-11-12
Completion
2021-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 40 mg Inhaled
Subject Voriconazole Small molecule 80 mg Inhaled

Indications